April 25 /PRNewswire/ -- Saint Luke's Mid America Heart Institute will be one of the first hospitals in the nation to offer the new CYPHER(TM) Sirolimus-eluting Stent, which today became the first drug-eluting stent
to receive marketing approval from the Food and Drug Administration (FDA) for the treatment of blocked coronary arteries.
In some ways, data from animal studies of drug-eluting stents
yield a better picture of long-term outcomes in humans than these short-term human studies do.
4 billion (reflecting worldwide coronary stent sales of approximately $540 million, of which approximately $180 million represent drug-eluting stent
sales) as compared to $2.
The Endeavor drug-eluting stent
system is an investigational device and not yet approved in the United States.
This study compared stents coated with MIVT's polymer-free drug-eluting technologies to the J&J Cypher(TM) stent, one of the world's best selling drug-eluting stents
We've submitted an extremely robust dossier on the Endeavor drug-eluting stent
, and we look forward to working with the FDA on an expeditious PMA review," said Scott Ward, president of the Vascular business at Medtronic.
Video Highlights Company's Strategies to Commercialize Medically Superior Drug-Eluting Stents
for $6 Billion Global Market
OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible drug-eluting stents
, announced today that it intends to begin the first human implants of a HAp NanoFilm coated stent early in 2007.
The overall cost of care for the first 12 months, including the initial stent placement, was an average of $309 more for each patient who received a drug-eluting stent
, reported Dr.
It also identifies the key players in the PCI drug-eluting stent
market and understand how this is likely to change with the advent of biodegradable stents.
The next major shakeup in the market will not come until early next year, when Medtronic is expected to get approval to market a third, competing brand of drug-eluting stent
A team of physicians from the Thorax Center in Rotterdam, the Netherlands, and from the Washington Hospital Center published the clinical details of four patients who developed stent thrombosis 11-14 months after receiving a drug-eluting stent